AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Ataxia-Telangiectasia

Recent research efforts aimed at curing Ataxia-Telangiectasia.

Last updated

Ataxia-Telangiectasia

Overview

Ataxia-telangiectasia (A-T) is a rare inherited disorder caused by harmful changes in both copies of the ATM gene. Loss of the ATM protein impairs the body’s response to DNA damage and affects the brain, immune system, lungs, and cancer risk. Classical A-T usually begins in early childhood with worsening problems in balance and coordination (ataxia), abnormal eye movements, slurred speech, recurrent respiratory infections, and eventually loss of independent mobility; people with “variant” A-T may retain some ATM activity and often have a milder, later-onset course. GeneReviews: Ataxia-Telangiectasia

Prognosis varies substantially by genetic subtype and complications, but progressive neurologic disability, chronic lung disease, immune dysfunction, and malignancy remain major causes of illness and early death. There is no established cure. Current care is multidisciplinary and supportive: infection prevention and treatment, immunoglobulin replacement when indicated, respiratory and nutritional support, physical/speech/occupational therapy, cancer surveillance, and careful avoidance of unnecessary ionizing radiation. GeneReviews: Ataxia-Telangiectasia

Scope of Recent Research (2020–present)

Research activity has accelerated from symptom control toward treatments that could alter the disease process, especially mutation-specific RNA medicines, restoration of ATM function, mitochondrial and NAD+ (nicotinamide adenine dinucleotide) support, and better biomarkers for trials. However, the field is not yet close to a broadly applicable cure: no therapy has demonstrated restoration of ATM throughout the brain, immune system, and other affected organs in people with A-T. FDA-supported antisense program Gene therapy vectors for A-T

Major Breakthroughs and Emerging Therapies

The most direct curative strategy is to repair or replace ATM. In 2020, researchers used CRISPR/Cas9 gene editing to correct disease-causing ATM variants in induced pluripotent stem cells—laboratory-grown cells reprogrammed from patients—and restored DNA-damage and oxidative-stress responses in the corrected cells. This was an important proof of principle, but it remains an ex vivo laboratory result rather than a treatment that can safely edit the many relevant cells in a person’s brain and body. CRISPR correction of patient A-T stem cells

Gene addition faces an unusual engineering barrier: the ATM coding sequence is about 9.2 kilobases, too large for many commonly used gene-delivery vectors. A 2023 vector comparison showed sharply lower viral production and cell transfer as vector size increased, illustrating why conventional single-vector replacement is difficult. More recently, investigators reported a dual lentiviral “split-intein” system that delivers two ATM halves into ATM-deficient cells; the halves reassemble into partially functional ATM protein and improve downstream ATM signaling and cell-cycle abnormalities. This approach is promising for autologous hematopoietic stem-cell gene therapy—modifying a patient’s own blood-forming stem cells outside the body—but it has not yet shown that it can protect the cerebellum or cure A-T in humans. Gene therapy vectors for A-T Split-intein lentiviral A-T gene therapy abstract

RNA therapeutics are advancing toward precision treatment for particular splice variants, which disrupt how a gene’s RNA message is assembled. Antisense oligonucleotides (ASOs) are short synthetic nucleic-acid drugs designed to bind RNA and redirect splicing. The FDA-supported atipeksen program targets the recurrent ATM c.7865C>T variant; in patient-derived cell lines, it corrected abnormal splicing and restored ATM function, and a clinical study is designed to assess neurological outcomes, imaging, and biomarkers in affected individuals. Separately, the UK Treat-AT program is testing ASOs for the ATM c.5763-1050A>G splice variant in patient fibroblasts and developing mutation-specific natural-history data needed for a future trial. These are potentially disease-modifying approaches, but they are applicable only to patients with the targeted variants and have not demonstrated a clinical cure. FDA-supported antisense program Treat-AT ASO development

A parallel strategy seeks to reduce downstream cellular damage rather than replace ATM. ATM-deficient cells show mitochondrial dysfunction, excessive inflammatory signaling, and depletion of NAD+, a molecule needed for energy metabolism and DNA-repair-related signaling. In A-T cells and mouse models, nicotinamide riboside (NR), an NAD+ precursor, improved mitophagy—the removal of damaged mitochondria—and reduced cellular senescence, neuroinflammation, neurodegeneration, and motor impairment in mice. Small human studies have also reported improved ataxia or coordination measures during NR treatment, but the studies were open-label or compared outcomes with historical data, so they cannot yet establish that NR changes long-term disease progression. NAD+ supplementation in A-T models NR proof-of-concept study Long-term NR study

Metabolic and neuroprotective medicines have produced the strongest recent clinical signals, although they are not genetic cures. In a 2025 phase 2a/b trial, triheptanoin—a synthetic dietary oil intended to replenish metabolic intermediates—improved nasal-cell-death and several motor, gait, fine-motor, and speech measures; gastrointestinal side effects often limited dose escalation. In 2026, a phase 3 trial of levacetylleucine, a modified amino acid, reported significantly better ataxia scores than placebo over 12-week treatment periods. These results may lead to meaningful symptom treatment and possibly slower deterioration, but neither approach restores the missing ATM gene or resolves immune and cancer risks. Triheptanoin phase 2a/b trial Levacetylleucine phase 3 trial

Clinical Trials and Experimental Approaches

The pivotal phase 3 IB1001-303 crossover trial of levacetylleucine enrolled 73 genetically confirmed pediatric and adult participants across ten hospitals and was funded by IntraBio. Mean Scale for the Assessment and Rating of Ataxia (SARA) scores improved by 1.92 points with levacetylleucine versus 0.14 points with placebo; the estimated treatment effect was −1.88 points (95% CI −2.70 to −1.06; p<0.0001). No treatment-related serious adverse events or deaths were reported, and an open-label extension is examining longer-term effects. Levacetylleucine phase 3 trial

The phase 3 NEAT trial tested erythrocyte-encapsulated dexamethasone sodium phosphate (eDSP, formerly EryDex) in 105 participants, sponsored by Quince Therapeutics. Although the treatment arm showed numerically less worsening on the RmICARS neurological scale at six months, the primary endpoint did not reach statistical significance (p=0.0851), nor did the key secondary endpoint; Quince announced in January 2026 that it would cease eDSP clinical development. NEAT trial record Quince NEAT topline results

Other notable experimental efforts include investigator-led NR studies, which found improved coordination and eye-movement measures over two years but lacked a randomized concurrent control group, and the Australia-based phase 2a/b triheptanoin study, funded by the Medical Research Future Fund, University of Queensland, Wesley Research Institute, and BrAshA-T. Mutation-specific atipeksen ASO treatment is also being evaluated through an FDA-supported clinical development program for people carrying ATM c.7865C>T. Long-term NR study Triheptanoin phase 2a/b trial FDA-supported antisense program

Methodologies and Scientific Approaches

Researchers combine patient-derived fibroblasts, induced pluripotent stem cells, neuron and microglia cultures, ATM-deficient cell lines, and mouse models to test whether an intervention restores ATM signaling, DNA repair, resistance to oxidative stress, mitochondrial function, or neuronal health. Gene-focused programs use CRISPR editing, ASO splice correction, and split-vector or split-protein gene delivery; these platforms are assessed first by measuring ATM RNA, ATM protein, phosphorylation of ATM target proteins, and correction of cell-cycle or DNA-damage phenotypes. CRISPR correction of patient A-T stem cells Split-intein lentiviral A-T gene therapy abstract

Clinical researchers are also improving trial readiness. Candidate outcome measures include SARA and ICARS ataxia scales, wearable movement monitoring, eye-tracking, MRI-based cerebellar measures, neurofilament light chain, alpha-fetoprotein, inflammatory/interferon signatures, and patient-reported function. The INSPIRE-AT natural-history study is following children with A-T using rating scales, activity wearables, computer-based target tracking, and biomarkers, while systematic review evidence emphasizes that many proposed biomarkers still need validation in larger longitudinal cohorts. INSPIRE-AT natural-history study A-T biomarker systematic review

Leading Institutions and Funding

Key contributors include Boston Children’s Hospital and the FDA-supported atipeksen program; the University of Cambridge, Cambridge University Hospitals NHS Trust, and the MRC Nucleic Acid Therapy Accelerator in UK ASO development; the University of Zurich, University Children’s Hospital Zurich, Paul-Ehrlich-Institut, and Goethe University Hospital Frankfurt in stem-cell-directed lentiviral gene therapy; Radboud University Medical Center and collaborators in NR research; and the University of Queensland and BrAshA-T in triheptanoin research. FDA-supported antisense program Treat-AT and lentiviral programs Triheptanoin phase 2a/b trial

Public and charitable investment remains important because A-T is rare. The FDA awarded Boston Children’s Hospital $3.58 million in fiscal year 2025 for the atipeksen ASO research program through August 2029. In the UK, Action Medical Research and Action for A-T have offered translational A-T project-grant opportunities, while the A-T Children’s Project supports one- or two-year basic, translational, and clinical grants of up to $75,000 per year in direct costs. FDA-supported antisense program Action Medical Research A-T grants A-T Children’s Project grant listing

Strengths, Limitations, and Challenges

A-T research now has credible therapeutic leads across several levels: genetic correction for selected mutations, blood-system gene therapy concepts, and randomized evidence that levacetylleucine can improve neurological function. The field also has better natural-history studies and emerging biomarkers, which are essential in a condition where progression differs by age, genotype, and clinical subtype. Levacetylleucine phase 3 trial INSPIRE-AT natural-history study A-T biomarker systematic review

The core limitations are formidable. A whole-body cure would need to restore ATM safely in difficult-to-reach brain cells as well as immune and other tissues; the size of ATM complicates gene delivery; ASOs are mutation-specific and may require repeated spinal-fluid dosing; and long-term editing, vector integration, immune reactions, off-target effects, cancer risk, and affordability must be addressed. Stem-cell transplantation can improve immune reconstitution in selected patients, but evidence for neurological benefit is inconsistent and transplantation itself carries substantial risks, so it is not a general cure for A-T. Gene therapy vectors for A-T FDA-supported antisense program HSCT systematic review

Outlook and Future Directions

As of October 9, 2026, A-T is not close to a universal cure, but the research trajectory is stronger than it was in 2020: a phase 3 symptomatic therapy has shown benefit, metabolic interventions have generated controlled-trial signals, and mutation-targeted ASOs have entered clinical development. The most important milestones to watch are long-term levacetylleucine extension data; independent, controlled confirmation of NR and triheptanoin findings; clinical safety and neurological results from atipeksen; validation of biomarkers that can shorten trials; and evidence that gene-delivery or editing approaches can safely restore ATM in both blood-forming cells and the central nervous system. Levacetylleucine phase 3 trial FDA-supported antisense program A-T biomarker systematic review

References

Don't see your disease? Request a report